Astellas Pharma Inc. and UMN Pharma Inc. today announced that the immunogenicity and favorable tolerability have been observed in Phase II clinical trial for the H5N1 influenza HA vaccine UMN-0501 (ASP7373). Astellas has been pursuing drug development of this vaccine in cooperation with UMN.